Wu S, Pascual D W, Lewis G K, Hone D M
Division of Infectious Diseases and Gastroenterology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21202, USA.
AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1187-94. doi: 10.1089/aid.1997.13.1187.
Previous studies from our group showed that a Salmonella-HIV vector vaccine that expressed recombinant HIV-1 envelope protein gp120 stably in the vector cytoplasm elicited type 1 helper T cell (Th1) responses to gp120. Despite the promise of such vaccines, a major limitation in their use was that multiple immunizations were required to elicit even small responses. For this reason, we sought a modified vector configuration that would induce more potent gp120-specific T cell responses exhibiting a broader spectrum of effector functions after a single inoculation. In this article we describe the construction and immunogenicity of a Salmonella-HIV vector that displays a truncated derivative of HIV-1(IIIB) envelope in the periplasm of the vector. A single oral dose of this Salmonella vector, called H683(pW58-asd+), generated a gp120-specific proliferation response in the spleen 14 days after immunization. In agreement with our previous findings, the gp120-specific splenic CD4+ T cells elicited by H683(pW58-asd+) displayed a Th1 phenotype; however, gp120-specific splenic CD4+ Th2 cells were also evident. In addition, this strain induced strong gp120-specific IgA antibody-secreting cell (ASC) responses in the intestinal lamina propria and mesenteric lymph nodes. As many as 2% of the total lamina propria and mesenteric lymph node IgA ASCs were found to be specific for gp120 28 days after a single oral dose of H683(pW57-asd+). Because the proliferative response following a single dose of H683(pW58-asd+) was comparable to that seen previously after three doses of an analogous construct expressing recombinant gp120 in the cytoplasm, these observations suggest that Salmonella-vectored secreted HIV-1 antigens elicit higher T cell responses than their cytoplasmically bound analogs.
我们团队之前的研究表明,一种沙门氏菌 - HIV载体疫苗在载体细胞质中稳定表达重组HIV - 1包膜蛋白gp120,可引发针对gp120的1型辅助性T细胞(Th1)反应。尽管这类疫苗前景广阔,但它们使用中的一个主要局限性是,即使要引发微弱反应也需要多次免疫。因此,我们寻求一种改良的载体构型,使其在单次接种后能诱导出更有效的gp120特异性T细胞反应,并展现出更广泛的效应功能谱。在本文中,我们描述了一种沙门氏菌 - HIV载体的构建及其免疫原性,该载体在载体周质中展示HIV - 1(IIIB)包膜的截短衍生物。单次口服这种名为H683(pW58 - asd +)的沙门氏菌载体后,在免疫14天后脾脏中产生了gp120特异性增殖反应。与我们之前的研究结果一致,H683(pW58 - asd +)引发的gp120特异性脾脏CD4 + T细胞表现出Th1表型;然而,gp120特异性脾脏CD4 + Th2细胞也很明显。此外,该菌株在肠固有层和肠系膜淋巴结中诱导出强烈的gp120特异性分泌IgA抗体的细胞(ASC)反应。单次口服H683(pW57 - asd +)28天后,发现肠固有层和肠系膜淋巴结中总IgA ASC的多达2%对gp120具有特异性。由于单次剂量的H683(pW58 - asd +)后的增殖反应与之前在细胞质中表达重组gp120的类似构建体三次剂量后的增殖反应相当,这些观察结果表明,沙门氏菌载体分泌的HIV - 1抗原比其细胞质结合类似物引发更高的T细胞反应。